Is Century Therapeutics Inc (IPSC) overvalued?
Century Therapeutics Inc (IPSC) is a biotechnology company listed on US.
This page asks whether Century Therapeutics Inc (IPSC) looks expensive on cached numbers — not a short thesis.
Latest reported IPSC revenue for 2024-12-31 was $6.6M. Net income was -$126.6M. Revenue was up 194.8% from 2023-12-31 to 2024-12-31. IPSC currently screens at market cap $47.8M.
IPSC currently screens at market cap $47.8M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next IPSC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the IPSC stock page for the full model, not this heading.
Not investment advice.